Are you Dr. Pryma?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 56 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
250 King of Prussia Rd
Chesterbrook, PA 19087Phone+1 800-789-7366Fax+1 215-662-7011- Is this information wrong?
Summary
- Dr. Daniel Pryma, MD is a board certified nuclear medicine physician in Chesterbrook, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New Jersey, and Florida. He is affiliated with Phoenixville Hospital, Penn Presbyterian Medical Center, and Philadelphia Veterans Affairs Medical Center.
Education & Training
Memorial Sloan Kettering Cancer CenterResidency, Nuclear Medicine, 2003 - 2005
Loyola University Medical CenterInternship, Internal Medicine, 2002 - 2003
Loyola University Chicago Stritch School of MedicineClass of 2002
Certifications & Licensure
NJ State Medical License 2014 - 2025
PA State Medical License 2005 - 2024
FL State Medical License 2014 - 2022
NY State Medical License 2003 - 2016
IL State Medical License 2002 - 2003- American Board of Nuclear Medicine Nuclear Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Start of enrollment: 2009 Jun 04
- FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Start of enrollment: 2010 Sep 01
- FDG PET/CT in Lung Cancer Staging Start of enrollment: 2016 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Prediction ofLu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation onGa-DOTATATE PET/CT.Niman, R., O'Brien, S., Eads, J., Lee, H., Kipnis, S., Katona, B., Pryma, D.> ;Cancers. 2023 Dec 31
- ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals.Paul E Wallner, Don C Yoo, Freddy E Escorcia, Carina Mari Aparici, Jeff Michalski, Michael Morris, Zachary S Morris, Daniel Pryma, Bryan M Rabatic, Navesh Sharma, Neha...> ;American Journal of Clinical Oncology. 2024 Apr 1
- Choosing the Right Metrics for Evaluation of Radiopharmaceutical Therapy Dosimetry Methodologies.Joshua S Scheuermann, Daniel A Pryma> ;Journal of Nuclear Medicine. 2023 Oct 1
- Join now to see all
Authored Content
- A Bright Future for Nuclear MedicineNovember 2018
Press Mentions
Neuroendocrine Cancer Program: Not a Rare Cancer at Penn MedicineOctober 4th, 2021- Awards & Accolades: May 2021June 9th, 2021
Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (Iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or ParagangliomaSeptember 17th, 2018- Join now to see all
Hospital Affiliations
Philadelphia Veterans Affairs Medical CenterPhiladelphia, Pennsylvania
Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
Pennsylvania HospitalPhiladelphia, Pennsylvania- Penn Presbyterian Medical CenterPhiladelphia, Pennsylvania
- Phoenixville HospitalPhoenixville, Pennsylvania
- Penn Medicine Chester County HospitalWest Chester, Pennsylvania
